Business
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company’s commercialization of early cancer detection and
About this update from Yd Bio Limited
[{"type":"image","alt":"YD Bio Limited","displaySize":"","headline":null,"caption":"YD Bio Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/2adf5e709359305c92390744828dcf90"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WR4LNNqWv_kaGTMDHNDb6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTQ2/https://media.zenfs.com/en/globenewswire.com/2adf5e709359305c92390744828dcf90","width":82,"height":34}},"lazy":false},{"type":"text","content":"Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company’s commercialization of early cancer detection and decentralized clinical service delivery across the United States.","length":565,"tagName":"p"},{"type":"text","content":"The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network of licensed physicians. This launch establishes scalable [digital] infrastructure designed to support both diagnostic service delivery and future clinical program expansion.","length":306,"tagName":"p"},{"type":"text","content":"The collaboration combines YD Bio’s digital health platform and commercialization strategy with EG BioMed’s CLIA/CAP-certified laboratory and diagnostic capabilities, creating an integrated ecosystem that connects patient access, physician oversight, and advanced cancer testing.","length":279,"tagName":"p"},{"type":"text","content":"Unlike traditional healthcare models, the EG Telehealth Platform introduces a decentralized, technology-driven approach that reduces friction in patient access while enabling rapid scaling of diagnostic services without reliance on physical infrastructure expansion.","length":266,"tagName":"p"},{"type":"text","content":"The platform supports detection and monitoring across multiple cancer types, including pancreatic, colorectal, liver, gastrointestinal, and breast cancers—addressing areas of significant unmet clinical need and growing demand ...